Severe Adverse Reaction to Vemurafenib in a Pregnant Woman with Metastatic Melanoma

Jorine de Haan, Johannes V. van Thienen, Michael Casaer, Rebekka A. Hannivoort, Kristel van Calsteren, Minke van Tuyl, Mathilde M. van Gerwen, Anne Debeer, Frédéric Amant, Rebecca C. Painter

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Targeted therapies have drastically changed the management of metastatic melanoma and have shown encouraging results on tumour progression but are also known for their high rates of adverse reactions. In general, targeted therapies are contraindicated during pregnancy due to concerns about teratogenesis. For the BRAF V600 inhibitor vemurafenib, the available literature about the effects on human pregnancy is limited to a single case report. In patients with metastatic melanoma that wish to continue their pregnancy, targeted therapies like vemurafenib offer the only possibility of improving maternal outcome. In this article, we report on a pregnant woman with metastatic melanoma who was treated with vemurafenib during pregnancy and experienced a fatal adverse reaction.
Original languageEnglish
Pages (from-to)119-124
JournalCase Reports in Oncology
Volume11
Issue number1
DOIs
Publication statusPublished - 2018

Cite this

de Haan, Jorine ; van Thienen, Johannes V. ; Casaer, Michael ; Hannivoort, Rebekka A. ; van Calsteren, Kristel ; van Tuyl, Minke ; van Gerwen, Mathilde M. ; Debeer, Anne ; Amant, Frédéric ; Painter, Rebecca C. / Severe Adverse Reaction to Vemurafenib in a Pregnant Woman with Metastatic Melanoma. In: Case Reports in Oncology. 2018 ; Vol. 11, No. 1. pp. 119-124.
@article{fd752c329c364663ae685720c4b1fe2a,
title = "Severe Adverse Reaction to Vemurafenib in a Pregnant Woman with Metastatic Melanoma",
abstract = "Targeted therapies have drastically changed the management of metastatic melanoma and have shown encouraging results on tumour progression but are also known for their high rates of adverse reactions. In general, targeted therapies are contraindicated during pregnancy due to concerns about teratogenesis. For the BRAF V600 inhibitor vemurafenib, the available literature about the effects on human pregnancy is limited to a single case report. In patients with metastatic melanoma that wish to continue their pregnancy, targeted therapies like vemurafenib offer the only possibility of improving maternal outcome. In this article, we report on a pregnant woman with metastatic melanoma who was treated with vemurafenib during pregnancy and experienced a fatal adverse reaction.",
author = "{de Haan}, Jorine and {van Thienen}, {Johannes V.} and Michael Casaer and Hannivoort, {Rebekka A.} and {van Calsteren}, Kristel and {van Tuyl}, Minke and {van Gerwen}, {Mathilde M.} and Anne Debeer and Fr{\'e}d{\'e}ric Amant and Painter, {Rebecca C.}",
year = "2018",
doi = "10.1159/000487128",
language = "English",
volume = "11",
pages = "119--124",
journal = "Case Reports in Oncology",
issn = "1662-6575",
number = "1",

}

de Haan, J, van Thienen, JV, Casaer, M, Hannivoort, RA, van Calsteren, K, van Tuyl, M, van Gerwen, MM, Debeer, A, Amant, F & Painter, RC 2018, 'Severe Adverse Reaction to Vemurafenib in a Pregnant Woman with Metastatic Melanoma' Case Reports in Oncology, vol. 11, no. 1, pp. 119-124. https://doi.org/10.1159/000487128

Severe Adverse Reaction to Vemurafenib in a Pregnant Woman with Metastatic Melanoma. / de Haan, Jorine; van Thienen, Johannes V.; Casaer, Michael; Hannivoort, Rebekka A.; van Calsteren, Kristel; van Tuyl, Minke; van Gerwen, Mathilde M.; Debeer, Anne; Amant, Frédéric; Painter, Rebecca C.

In: Case Reports in Oncology, Vol. 11, No. 1, 2018, p. 119-124.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Severe Adverse Reaction to Vemurafenib in a Pregnant Woman with Metastatic Melanoma

AU - de Haan, Jorine

AU - van Thienen, Johannes V.

AU - Casaer, Michael

AU - Hannivoort, Rebekka A.

AU - van Calsteren, Kristel

AU - van Tuyl, Minke

AU - van Gerwen, Mathilde M.

AU - Debeer, Anne

AU - Amant, Frédéric

AU - Painter, Rebecca C.

PY - 2018

Y1 - 2018

N2 - Targeted therapies have drastically changed the management of metastatic melanoma and have shown encouraging results on tumour progression but are also known for their high rates of adverse reactions. In general, targeted therapies are contraindicated during pregnancy due to concerns about teratogenesis. For the BRAF V600 inhibitor vemurafenib, the available literature about the effects on human pregnancy is limited to a single case report. In patients with metastatic melanoma that wish to continue their pregnancy, targeted therapies like vemurafenib offer the only possibility of improving maternal outcome. In this article, we report on a pregnant woman with metastatic melanoma who was treated with vemurafenib during pregnancy and experienced a fatal adverse reaction.

AB - Targeted therapies have drastically changed the management of metastatic melanoma and have shown encouraging results on tumour progression but are also known for their high rates of adverse reactions. In general, targeted therapies are contraindicated during pregnancy due to concerns about teratogenesis. For the BRAF V600 inhibitor vemurafenib, the available literature about the effects on human pregnancy is limited to a single case report. In patients with metastatic melanoma that wish to continue their pregnancy, targeted therapies like vemurafenib offer the only possibility of improving maternal outcome. In this article, we report on a pregnant woman with metastatic melanoma who was treated with vemurafenib during pregnancy and experienced a fatal adverse reaction.

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85042136446&origin=inward

UR - https://www.ncbi.nlm.nih.gov/pubmed/29606950

U2 - 10.1159/000487128

DO - 10.1159/000487128

M3 - Article

VL - 11

SP - 119

EP - 124

JO - Case Reports in Oncology

JF - Case Reports in Oncology

SN - 1662-6575

IS - 1

ER -

de Haan J, van Thienen JV, Casaer M, Hannivoort RA, van Calsteren K, van Tuyl M et al. Severe Adverse Reaction to Vemurafenib in a Pregnant Woman with Metastatic Melanoma. Case Reports in Oncology. 2018;11(1):119-124. https://doi.org/10.1159/000487128